Promega Sells Rights to DNA Technology to Chemicon Int’l.

Madison, Wis – Promega Corporation and Chemicon International, Inc. announced today a sub-license agreement in which Chemicon may use and apply Madison-based Promega’s DNA-directed, RNA interference (ddRNAi) technology.

Under the agreement, Chemicon, California-based division of Serologicals Corporation, will have the right to use the technology to develop and sell ddRNAi-based products and reagents for life science research. Promega will also provide Chemicon with proprietary materials that will support Chemicon’s development of enabling products for the study of the role of genes in mammalian physiology. Promega is the exclusive global licensee in certain fields for the proprietary ddRNAi technology. Financial terms were not disclosed.